natgillin/translations-raw huggingface dataset:
Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, numbness or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors.
S primjenom kinolonskih i fluorokinolonskih antibiotika povezuju se vrlo rijetki slučajevi dugotrajnih (koje traju čak mjesecima ili godinama) ili trajnih nuspojava, kao što su upala tetive, puknuće tetive, bol u zglobovima, bol u udovima, otežano hodanje, abnormalni osjeti poput bockanja, trnaca, škakljanja, žarenja, utrnulosti ili boli (neuropatija), depresija, umor, poremećaji spavanja, narušeno pamćenje, kao i oštećenje sluha, vida te okusa i njuha, koje u nekim slučajevima nastaju neovisno o prethodno prisutnim čimbenicima rizika.
A total of 189 patients were randomised to Quinsair 240 mg twice daily (≥ 18 years, n = 170; ≥ 12 to < 18 years old, n = 19) and 93 were randomised to TIS (≥ 18 years, n = 84; ≥ 12 to < 18 years old, n = 9).
≥ 12 do < 18godina, n = 19) i 93 bolesnika je randomizirano u skupinu koja je primala TIS (u dobi ≥ 18 godina, n = 84; i u dobi ≥ 12 do < 18 godina, n = 9).
Respiratory, thoracic and mediastinal disorders
Poremećaji dišnog sustava, prsišta i sredoprsja alergijski pneumonitis
You should not take fluoroquinolone/quinolone antibacterial medicines, including Quinsair, if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone.
Ako ste ikad prije imali neku ozbiljnu nuspojavu kad ste uzimali kinolon ili fluorokinolon, ne smijete uzimati fluorokinolonske/kinolonske antibiotike, što uključuje i Quinsair.
Baseline to Day 28 of Cycle 1
Promjene od početnih vrijednosti do 28. dana 1. ciklusa
What Quinsair looks like and contents of the pack Quinsair is a clear, pale yellow nebuliser solution.
Kako Quinsair izgleda i sadržaj pakiranja
General disorders and administration site conditions1
Opći poremećaji i reakcije na mjestu primjene1
Cycles 1 to 6), the LS Mean change in FEV1 percent predicted ranged between 3.6% to 4.6% except in Cycle 6, where it was close to baseline (-0.15%).
U podskupini bolesnika koji su primali Quinsair tijekom čitave središnje faze i produžene faze ispitivanja (tj. od 1. do 6. ciklusa terapije), srednja LS promjena postotka predviđene vrijednosti FEV1 kretala se između 3,6% i 4,6%, osim u 6. ciklusu kada je bila slična početnim vrijednostima (-0.15%).
Cardiac disorders
Srčani poremećaji tahikardija*
- Do not put any medicines other than Quinsair in the Zirela Nebuliser Handset.
- U napravu za inhalaciju Zirela Nebuliser Handset ne stavljajte druge lijekove osim Quinsaira.
FEV1 Relative change from Baseline to Day 28 of Cycle 2
Sekundarne krajnje točke ishoda: Relativna promjena FEV1 od početnih vrijednosti do 28. dana 2. ciklusa
If this happens, stop using Quinsair and contact your doctor immediately.
Ako se to dogodi, odmah se obratite svom liječniku.
The half-life of levofloxacin following inhalation of Quinsair is approximately 5 to 7 hours.
Poluvijek levofloksacina nakon inhalacije Quinsaira iznosi oko
Nebuliser Solution Levofloxacin
Otopina za atomizator levofloksacin
Benign intracranial hypertension
Krvožilni poremećaji hipotenzija
N = 166 1.98 (1.049) b
N = 166 1,98 (1,049) b srednja LS [95% CI]:
Adare Pharmaceuticals S.r.l.
Chiesi Pharmaceuticals B.V.
Headache, Dizziness*
disgeuzija glavobolja, omaglica*
PHARMACEUTICAL FORM Nebuliser solution.
OBLIK Otopina za atomizator.
Eye disorders1
Poremećaji oka1
Posology
Oznaka
Changes in bronchial secretions (volume and viscosity)*, Haemoptysis*
Poremećaji dišnog sustava, prsišta i sredoprsja kašalj / produktivni kašalj dispneja, promjene u bronhalnoj sekreciji (volumena i viskoziteta)*, hemoptiza*
Chiesi Bulgaria EOOD Teл.
Magyarország Chiesi Hungary Kft.
Clear, pale yellow solution.
Bistra, blijedožuta otopina.
Ampoule
Doziranje
Retching, Dyspepsia*, Flatulence*
dizanje želuca, dispepsija*, vjetrovi*
Haemoptysis
Ampula
0.65 ml (200 µg/ml) 4 pre-filled pens
0,65 ml (200 µg/ml) 4 napunjene štrcaljke
0.65 ml (200 µg/ml) 4 pre-filled syringes with needle guard
0,65 ml (200 µg/ml) 4 štrcaljke s uloškomsa štitnikom za iglu
0.65 ml (200 µg/ml) 1 pre-filled syringe with needle guard
0,65 ml (200 µg/ml) 1 štrcaljka s uloškom sa štitnikom za iglu
Aripiprazole Mylan Pharma is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription.
Lijek Aripiprazole Mylan Pharma dostupan je u tabletama (5, 10, 15 i 30 mg), a izdaje se samo na recept.
The name of the medicine was changed to Aripiprazole Mylan Pharma on 3 June 2016.
Naziv lijeka izmijenjen je u Aripiprazole Mylan Pharma 3. lipnja 2016.
For more information on generic medicines, see the question-andanswer document here.
Više informacija o generičkim lijekovima potražite u dokumentu s pitanjima i odgovorima ovdje
The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Mylan Pharma is broken down in the body.
Dozu treba prilagoditi u bolesnika koji uzimaju druge lijekove, koji mogu utjecati na način razgradnje lijeka Aripiprazole Mylan Pharma u tijelu.
In addition, the company that markets Aripiprazole Mylan Pharma will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years.
Nadalje, proizvođač lijeka Aripiprazole Mylan Pharma dostavit će edukacijske materijale koji će se uručiti bolesnicima ili njihovim skrbnicima i liječnicima kako bi se pojasnila sigurna primjena lijeka u bolesnika u dobi između 13 i 17 godina.
This is a summary of the European public assessment report (EPAR) for Aripiprazole Mylan Pharma.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Aripiprazole Mylan Pharma.
The Committee recommended that Aripiprazole Mylan Pharma be approved for use in the EU.
Odbor je preporučio odobrenje lijeka Aripiprazole Mylan Pharma za korištenje u EU-u.
Aripiprazole Mylan Pharma is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Aripiprazole Mylan Pharma se koristi u odraslih osoba za liječenje umjerenih do ozbiljnih maničnih epizoda i za sprječavanje novih maničnih epizoda u odraslih osoba koje su odgovorile na lijek u prošlosti.
Aripiprazole Mylan Pharma is used in patients with the following mental illnesses:
Aripiprazole Mylan Pharma koristi se u bolesnika sa sljedećim mentalnim bolestima:
This means that Aripiprazole Mylan Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify.
To znači da je Aripiprazole Mylan Pharma sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Abilify.
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno kako Aripiprazole Mylan Pharma posjeduje usporedivu kakvoću te je bioekvivalentan s lijekom Abilify.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Mylan Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Aripiprazole Mylan Pharma nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Because Aripiprazole Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Budući da je lijek Aripiprazole Mylan Pharma generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i kod referentnog lijeka.
For practical information about using Aripiprazole Mylan Pharma, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju lijeka Aripiprazole Mylan Pharma bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
Aripiprazole Mylan Pharma is used in patients aged 15 years or over;
Aripiprazole Mylan Pharma se koristi u bolesnika u dobi od 15 godina ili starijih;
Aripiprazole Mylan Pharma is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Aripiprazole Mylan Pharma se također koristi u razdoblju do 12 tjedana za liječenje umjerenih do ozbiljnih maničnih epizoda u bolesnika u dobi od 13 godina i starijih.
What is Aripiprazole Mylan Pharma and what is it used for?
Što je Aripiprazole Mylan Pharma i za što se koristi?
Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine'.
Aripiprazole Mylan Pharma sadrži djelatnu tvar aripiprazol i "generički je lijek".
The full EPAR and risk management plan summary for Aripiprazole Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Aripiprazole Mylan Pharma nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Aripiprazole Mylan Pharma pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
What measures are being taken to ensure the safe and effective use of Aripiprazole Mylan Pharma?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Aripiprazole Mylan Pharma?
A risk management plan has been developed to ensure that Aripiprazole Mylan Pharma is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Aripiprazole Mylan Pharma.
What are the benefits and risks of Aripiprazole Mylan Pharma?
Koje su koristi i rizici od lijeka Aripiprazole Mylan Pharma?
Because Aripiprazole Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify.
Budući da je Aripiprazole Mylan Pharma generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje da je lijek bioekvivalentan referentnom lijeku Abilify.
It is not intended to provide practical advice on how to use Aripiprazole Mylan Pharma.
Svrha sažetka nije davati praktične savjete o primjeni lijeka Aripiprazole Mylan Pharma.
Other information about Aripiprazole Mylan Pharma
Ostale informacije o lijeku Aripiprazole Mylan Pharma
The active substance in Aripiprazole Mylan Pharma, aripiprazole, is an antipsychotic medicine.
Aripiprazol, djelatna tvar u lijeku Aripiprazole Mylan Pharma, je antipsihotik.
Why is Aripiprazole Mylan Pharma approved?
Zašto je lijek Aripiprazole Mylan Pharma odobren?
Previously known as Aripiprazole Pharmathen.
Ranije poznat pod imenom Aripiprazole
The European Commission granted a marketing authorisation valid throughout the European Union for Aripiprazole Pharmathen on 30 June 2015.
Pharmathen na snazi u Europskoj uniji od 30. lipnja 2015.
Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk.
Stoga je stav CHMP-a da u pogledu lijeka Aripiprazole Mylan Pharma koristi nadmašuju utvrđene rizike.
How is Aripiprazole Mylan Pharma used?
Kako se koristi Aripiprazole Mylan Pharma?
How does Aripiprazole Mylan Pharma work?
Kako djeluje Aripiprazole Mylan Pharma?
How has Aripiprazole Mylan Pharma been studied?
Kako je Aripiprazole Mylan Pharma ispitivan?
Date of first authorisation: 3 October 2011 Date of latest renewal: 9 June 2016
Datum posljednje obnove odobrenja: 9. lipnja 2016.
It is important that you take Telmisartan Teva Pharma every day until your doctor tells you otherwise.
Važno je uzimati Telmisartan Teva Pharma svaki dan, dok Vam liječnik ne kaže drugačije.
Do not take a double dose to make up for forgotten individual doses.
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
• Amifostine (a protective medicine during radiotherapy for cancer treatment)
• Amifostin (lijek koji se koristi tijekom radioterapije pri liječenju raka)
You can take Telmisartan Teva Pharma with or without food.
Možete uzimati Telmisartan Teva Pharma sa ili bez hrane.
Corticosteroïds (systemic route) Reduction of the antihypertensive effect.
Kortikosteroidi (sistemski put primjene) Smanjenje antihipertenzivnog učinka.
• Baclofen (a muscle relaxant)
• Baklofen (mišićni relaksans)
If you have the impression that the effect of Telmisartan Teva Pharma is too strong or too weak, talk to your doctor or pharmacist.
Ako mislite da je učinak Telmisartana Teva Pharma prejak ili preslab, razgovarajte sa svojim liječnikom ili ljekarnikom.
Your doctor will normally advise you to stop taking Telmisartan Teva Pharma before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Teva Pharma.
Liječnik će Vam obično savjetovati da prestanete uzimati Telmisartan Teva Pharma prije nego ostanete trudni ili čim saznate da ste trudni te će Vam savjetovati uzimanje drugog lijeka umjesto Telmisartana Teva Pharma.
The inhibitory effect is maintained over 24 hours and still measurable up to 48 hours.
Inhibitorni učinak se održava tijekom 24 sata, a još uvijek se može izmjeriti do
Possible side effects of telmisartan:
Moguće nuspojave telmisartana:
Your doctor may need to change the dose of these other medicines or take other precautions.
Liječnik će Vam možda morati promijeniti dozu i/ ili poduzeti druge mjere opreza.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet:
Eastbourne, East Sussex, BN22 9AG United Kingdom
Eastbourne, East Sussex, BN22 9AG
CLINICAL PARTICULARS 4.1 Therapeutic indications
KLINIČKI PODACI 4.1 Terapijske indikacije Hipertenzija
- The active substance is telmisartan.
- Djelatna tvar je telmisartan.
There are no adequate data from the use of Telmisartan Teva Pharma in pregnant women.
Ne postoje odgovarajući podaci o primjeni Telmisartana Teva Pharma u trudnica.
The event may be a chance finding or related to a mechanism currently not known (see section
Taj događaj može biti slučajan ili povezan s trenutno nepoznatim mehanizmom (također vidjeti dio 5.1).
What Telmisartan Teva Pharma is and what it is used for
Što je Telmisartan Teva Pharma i za što se koristi
In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Teva Pharma.
U slučaju kirurškog zahvata ili anestezije, trebate obavijestiti svog liječnika da uzimate Telmisartan
- if you have severe liver problems such as cholestasis or biliary obstruction (problems with the drainage of the bile from the liver and gall bladder) or any other severe liver disease.
- ako imate teške probleme s jetrom kao što su kolestaza ili bilijarna opstrukcija (problemi s drenažom žuči iz jetre i žučnog mjehura) ili neku drugu tešku bolest jetre.
Elderly No dose adjustment is necessary for elderly patients.
Nije potrebno prilagođavati dozu u starijih bolesnika.
Telmisartan Teva Pharma contains sorbitol.
Telmisartan Teva Pharma sadrži sorbitol.
Serious adverse drug reactions include anaphylactic reaction and angioedema which may occur rarely (≥1/10,000 to <1/1,000), and acute renal failure.
Teške nuspojave obuhvaćaju anafilaktičku reakciju i angioedem koji se mogu rijetko pojaviti (≥1/10 000 i < 1/1000) i akutno zatajenje bubrega.
There is no experience regarding the administration of Telmisartan Teva Pharma in patients with recent kidney transplantation.
Ne postoji iskustvo u vezi primjene Telmisartana Teva Pharma u bolesnika kojima je nedavno transplantiran bubreg.
Telmisartan Teva Pharma is used to treat essential hypertension (high blood pressure) in adults.
Telmisartan Teva Pharma se primjenjuje u liječenju esencijalne hipertenzije (visoki krvni tlak) u odraslih osoba.
Telmisartan Teva Pharma is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Telmisartan Teva Pharma se ne preporučuje dojiljama te Vaš liječnik može odabrati drugo liječenje za Vas ako želite dojiti, osobito ako je Vaše dijete novorođenče ili je prerano rođeno.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Aluminium-Aluminium peelable perforated unit-dose blisters and aluminium-aluminium perforated unitdose blisters.
Aluminij-Aluminij perforirani blisteri s odvojivim slojem djeljivi na jedinične doze i aluminij-aluminij perforirani blisteri djeljivi na jedinične doze.
Telmisartan Teva Pharma belongs to a class of medicines known as angiotensin-II receptor antagonists.
Telmisartan Teva Pharma pripada skupini lijekova poznatih kao antagonisti receptora angiotenzina II.
If you take more Telmisartan Teva Pharma than you should
Ako uzmete više Telmisartana Teva Pharma nego što ste trebali
Before considering the concomitant use of medicinal products that affect the renin-angiotensinaldosterone system, the benefit risk ratio should be evaluated.
Prije razmatranja istodobne primjene lijekova koji utječu na sustav renin-angiotenzinaldosteron, potrebno je procijeniti omjer koristi i rizika.
Tel/Tél: +32 3 820 73 73
Tél/Tel: +32 3 820 73 73
Because no information is available regarding the use of Telmisartan Teva Pharma during breast-feeding, Telmisartan Teva Pharma is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Budući da ne postoje dostupni podaci o primjeni Telmisartana Teva Pharma tijekom dojenja, primjena Telmisartana Teva Pharma se ne preporučuje i prednost se daje drugim lijekovima s bolje utvrđenim sigurnosnim profilima tijekom dojenja, osobito tijekom razdoblja dojenja novorođenčeta ili nedonoščeta.
See also information under the heading “Do not take Telmisartan Teva Pharma”.
Vidjeti također informacije pod naslovom “Nemojte uzimati Telmisartan Teva Pharma“.
Telmisartan tablets are for once-daily oral administration and should be taken with liquid, with or without food.
Način primjene Telmisartan tablete primjenjuju se peroralno jednom dnevno i trebaju se uzimati s tekućinom, sa ili bez hrane.
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskirenom kontrainidirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
HU-4042 Debrecen
H-4042 Debrecen,
The effect of Telmisartan Teva Pharma may be reduced when you take NSAIDs (non steroidal antiinflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinak Telmisartana Teva Pharma se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
Telmisartan Teva Pharma is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes.
Telmisartan Teva Pharma se također primjenjuje za smanjivanje kardiovaskularnih događaja (tj. srčanog udara ili moždanog udara) u rizičnih odraslih osoba koji imaju smanjenu ili prekinutu opskrbu krvlju srca ili nogu, ili su imali moždani udar, ili imaju šećernu bolest s visokim rizikom za oštećenje organa.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Omjer hazarda za telmisartan u odnosu na ramipril bio je 1,01 (97,5 % CI 0,93 - 1,10, p (neinferiornost) = 0,0019 na granici od 1,13).
Symptomatic hypotension, especially after the first dose of Telmisartan Teva Pharma, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Simptomatska hipotenzija, osobito nakon prve doze Telmisartana Teva Pharma, može se pojaviti u bolesnika koji imaju depleciju volumena i/ili natrija zbog snažne terapije diureticima, prehrane s ograničenim unosom soli, proljeva ili povraćanja.
This applies especially to the medicines listed below taken at the same time with Telmisartan Teva Pharma.
Ovo se osobito odnosi na lijekove koji su navedeni u nastavku, a uzimaju se istovremeno s Telmisartanom Teva Pharma:
Telmisartan Teva Pharma is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.
Telmisartan Teva Pharma se ne smije davati bolesnicima s kolestazom, bilijarnom opstrukcijom ili teškim oštećenjem jetrene funkcije (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
For reduction of cardiovascular events, the usual dose of Telmisartan Teva Pharma is one 80 mg tablet once a day.
Za smanjivanje kardiovaskularnih događaja, uobičajena doza Telmisartana Teva Pharma je jedna tableta od 80 mg, jedanput na dan.
The recommended dose of Telmisartan Teva Pharma is one tablet a day.
Preporučena doza Telmisartana Teva Pharma je jedna tableta dnevno.
Other medicines and Telmisartan Teva Pharma
Drugi lijekovi i Telmisartan Teva Pharma
When Telmisartan Teva Pharma is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
Kada se Telmisartan Teva Pharma primjenjuje u bolesnika s poremećenom funkcijom bubrega, preporučuje se povremeno pratiti vrijednosti kalija i kreatinina u serumu.
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000).
Hypotension2, orthostatic hypotension
2, ortostatska hipotenzija
What Telmisartan Teva Pharma looks like and contents of the pack
Kako Telmisartan Teva Pharma izgleda i sadržaj pakiranja
Telmisartan Teva Pharma is contraindicated in patients with severe hepatic impairment (see section 4.3).
Telmisartan Teva Pharma je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3).
Some people feel dizzy or tired when they taking Telmisartan Teva Pharma.
Neki ljudi osjećaju omaglicu ili umor kada uzimaju Telmisartan Teva Pharma.
Telmisartan Teva Pharma may be less effective in lowering the blood pressure in black patients.
Telmisartan Teva Pharma može biti manje učinkovita u snižavanju krvnog tlaka u bolesnika crne rase.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Stenoza aortnog i mitralnog zaliska, opstruktivna hipertrofička kardiomiopatija Kao i s ostalim vazodilatatorima, potreban je poseban oprez u bolesnika koji imaju aortalnu ili mitralnu stenozu ili opstruktivnu hipertrofičnu kardiomiopatiju.